Anti-HVEM antibodies can disrupt HVEM-mediated suppression of T-cell responses, while HVEM-Fc fusion proteins have shown promise in lung cancer models as decoys to rewire signaling [326]. The gene discussed is TNFRSF14; the disease is lung carcinoma.